We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood Tests Can Detect Inflammatory Bowel Diseases Years before Diagnosis

By LabMedica International staff writers
Posted on 08 Nov 2023
Print article
Image: The researchers looked at several clinical tests up to 10 years before inflammatory bowel disease diagnosis (Photo courtesy of M. Cell Reports Medicine)
Image: The researchers looked at several clinical tests up to 10 years before inflammatory bowel disease diagnosis (Photo courtesy of M. Cell Reports Medicine)

Inflammatory bowel diseases (IBD), which include Crohn's disease and ulcerative colitis, are chronic conditions that lead to ongoing inflammation in the digestive tract. This results in discomfort and symptoms such as stomach pain and persistent diarrhea. Recognizing and managing these conditions early is crucial for better patient outcomes. Past assumptions held that most patients experienced symptoms approximately one year prior to being diagnosed. However, the presence of significant damage to the bowels at the time of diagnosis indicated that these diseases might have been developing for a much more extended period. Now, new research has revealed that certain signs of Crohn’s disease can be identified through blood tests up to eight years before its diagnosis, and signs of ulcerative colitis can be detected up to three years prior.

This research, carried out by investigators at the Francis Crick Institute (London, UK) and Aalborg University (Copenhagen, Denmark), highlights that the onset of inflammatory bowel diseases occurs well before symptoms manifest. This discovery opens the possibility for healthcare providers to intervene preemptively or to start treatment at an earlier, potentially more effective stage. The researchers reached their findings by reviewing ten years of blood test results leading up to an IBD diagnosis. They noted variations in specific blood minerals, cell counts, and inflammation indicators, including fecal calprotectin—a marker released during bowel inflammation and currently used to decide if a person with gastrointestinal complaints should undergo more detailed examinations. These variations became noticeable up to eight years before Crohn's disease was diagnosed and three years before ulcerative colitis was diagnosed.

What's particularly noteworthy is that many of these changes were minor and fell within what would be considered normal ranges in standard blood tests, meaning they wouldn't typically trigger alarms for further action. It took a comprehensive analysis of a large volume of data to spot these subtle changes among various indicators. The researchers aim to delve further, exploring whether initiating treatment or preventive measures before symptoms appear could be beneficial, and examining whether these research insights could help predict who might develop IBD in the future.

“Our research shows that the bowel damage we’re seeing at the point of diagnosis is just the tip of the iceberg. So many changes are subtly taking place in the body before the disease takes hold,” said James Lee, Group Leader of the Genetic Mechanisms of Disease Laboratory at the Crick. “This has huge implications for prevention as it highlights that there’s a window of opportunity for treatment.”

“Our findings are novel and go hand-in-hand with emerging evidence that chronic inflammatory bowel diseases likely have their onset years prior to diagnosis,” added Tine Jess, Director at the Center for Molecular Prediction of Inflammatory Bowel Disease, PREDICT, at Aalborg University.

Related Links:
Francis Crick Institute
Aalborg University

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.